Core Insights - Sernova Corp. held its annual and special general meeting on January 10, 2025, with 74,190,067 common shares voted, representing 22.8% of all outstanding shares as of November 12, 2024 [1] Group 1: Shareholder Meeting Outcomes - Six directors were elected with high approval rates, including Tanya Lewis (99.6%), Bernd Muehlenweg (99.7%), and David Paterson (99.4%) [2] - The Board expressed satisfaction with shareholder support, indicating a new era for the company with a strengthened management team and corporate branding [3] Group 2: Company Overview - Sernova Corp. is focused on developing regenerative medicine therapeutics, specifically a bio-hybrid organ for type 1 diabetes and thyroid disorders [3] - The bio-hybrid organ integrates living cells with non-living materials to restore normal organ function, representing a potentially revolutionary treatment for chronic diseases [3] Group 3: Corporate Governance and Structure - KPMG LLP was appointed as auditors until the next annual meeting [5] - The company will continue as a British Columbia corporation and has adopted new articles, altering its authorized share structure to include an unlimited number of Preferred Shares [5] - The maximum number of common shares reserved for stock option grants has been increased to 50,000,000, with a conditional grant of 5,500,000 options to officers [5]
Sernova Announces Voting Results from its Annual and Special General Meeting of Shareholders